Compare PRIM & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRIM | BIO |
|---|---|---|
| Founded | 1960 | 1952 |
| Country | United States | United States |
| Employees | 18526 | 7450 |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.9B |
| IPO Year | 2006 | N/A |
| Metric | PRIM | BIO |
|---|---|---|
| Price | $103.72 | $295.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 4 |
| Target Price | $155.20 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.8M | 427.4K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.19% | N/A |
| EPS Growth | ★ 51.66 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.92 | $2.74 |
| Revenue Next Year | $8.80 | $3.20 |
| P/E Ratio | $383.81 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.84 | $222.80 |
| 52 Week High | $205.50 | $343.12 |
| Indicator | PRIM | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 54.72 |
| Support Level | $100.83 | $293.88 |
| Resistance Level | $122.33 | $314.39 |
| Average True Range (ATR) | 8.44 | 9.57 |
| MACD | 0.55 | -0.10 |
| Stochastic Oscillator | 9.42 | 46.11 |
Primoris Services Corp is a provider of critical infrastructure services operating mainly in the United States and Canada. The company provides a range of construction, maintenance, replacement, and engineering services. The Utilities segment operates throughout the United States and specializes in a range of services, including the construction and maintenance of new and existing natural gas and electric utility distribution and transmission systems, and communications systems. The Energy segment operates throughout the United States and Canada and specializes in a range of services that include engineering, procurement, construction, and maintenance services to various industries. The majority of the company's revenue is derived from the Energy segment.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.